Aradhana Sarin
President at ACHILLION PHARMACEUTICALS, INC.
Net worth: 11 M $ as of 2024-03-30
Profile
Dr. Aradhana Sarin is a President & Director at Achillion Pharmaceuticals, Inc. and a Chief Financial Officer & Executive Vice President at Alexion Pharmaceuticals, Inc. He is on the Board of Directors at Achillion Pharmaceuticals, Inc. Dr. Sarin was previously employed as an Independent Director by OraSure Technologies, Inc., a MD-Healthcare Corporate & Investment Banking by Citizens, Inc. (Austin, Texas), and a Managing Director-Healthcare Investment Banking by UBS AG. He received his MBA from Stanford Graduate School of Business.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
ASTRAZENECA PLC
0.01% | 2023-12-30 | 82,514 ( 0.01% ) | 11 M $ | 2024-03-30 |
Latest news about Aradhana Sarin
Aradhana Sarin active positions
Companies | Position | Start |
---|---|---|
ACHILLION PHARMACEUTICALS, INC. | President | 2020-01-27 |
ASTRAZENECA PLC | Director of Finance/CFO | 2021-07-31 |
ANHEUSER-BUSCH INBEV SA/NV | Director/Board Member | 2023-04-25 |
Former positions of Aradhana Sarin
Companies | Position | End |
---|---|---|
CITIZENS, INC. | Corporate Officer/Principal | 2017-09-30 |
UBS | Corporate Officer/Principal | - |
ALEXION PHARMACEUTICALS, INC. | Director of Finance/CFO | - |
ORASURE TECHNOLOGIES, INC. | Director/Board Member | - |
Training of Aradhana Sarin
University of Delhi | Doctorate Degree |
Stanford Graduate School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 4 |
---|---|
CITIZENS, INC. | Finance |
ASTRAZENECA PLC | Health Technology |
ORASURE TECHNOLOGIES, INC. | Health Technology |
ANHEUSER-BUSCH INBEV SA/NV | Consumer Non-Durables |
Private companies | 3 |
---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
UBS AG
UBS AG Investment ManagersFinance UBS AG engages in the provision of financial advisory solutions for private and institutional investors, intermediaries, and wealth management clients. The firm focuses on the areas of wealth and asset management, as well as investment banking. It offers retail investment products, global financing services, investment research, bespoke financing, traditional investments, as well as bonds and equities. The company was founded in 1862 and is headquartered in Zurich, Switzerland. | Finance |
Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
- Stock Market
- Insiders
- Aradhana Sarin